Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Molecular Profile | PIK3CA mut PTEN loss |
Therapy | Alpelisib |
Indication/Tumor Type | breast cancer |
Response Type | resistant |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
PIK3CA mut PTEN loss | breast cancer | resistant | Alpelisib | Case Reports/Case Series | Actionable | In a clinical case study, a breast cancer patient harboring a PIK3CA mutation developed resistance to Alpelisib (BYL719) treatment and progressive disease after initial response, accompanied by a loss of PTEN, and the corrresponding patient-derived xenograft model demonstrated resistance to Alpelisib (BYL719)-induced inhibition of tumor growth (PMID: 25409150). | detail... 25409150 |
PubMed Id | Reference Title | Details |
---|---|---|
Loss of PTEN leads to clinical resistance to the PI3K? inhibitor BYL719 and provides evidence of convergent evolution under selective therapeutic pressure | Full reference... | |
(25409150) | Convergent loss of PTEN leads to clinical resistance to a PI(3)Kα inhibitor. | Full reference... |